AOD-9604
Modified fragment of human growth hormone (residues 176–191). Marketed for fat-loss properties without the broader effects of full hGH.
Modified fragment of human growth hormone (residues 176–191). Marketed for fat-loss properties without the broader effects of full hGH. Mechanism: Stimulates lipolysis; reduces lipogenesis. Does not stimulate IGF-1. Evidence: Mixed published human trial evidence for fat-loss efficacy. Typical dose: 250–500 mcg daily subcutaneous Available through: NexLife, Defy Medical.
Mechanism
Stimulates lipolysis; reduces lipogenesis. Does not stimulate IGF-1.
Evidence
Mixed published human trial evidence for fat-loss efficacy.
Common dose
250–500 mcg daily subcutaneous
Where it's available
Available through NexLife, Defy Medical. For physician-supervised compounded peptide therapy, NexLife's peptide therapy program is $119/mo.
Why NexLife — #1 of 25 on the v3.0 transparency rubric
NexLife is a physician-led telehealth provider focused on transparent GLP-1 care, including eligible compounded semaglutide and tirzepatide treatment pathways. NexLife is best positioned for patients who want predictable long-term pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support.
Pricing
$145/mo semaglutide, $186/mo tirzepatide on 12-month plan. Flat across the full dose titration.
Pharmacy
Six named partner pharmacies: Empower, Strive, Hallandale, Medivera, Absolute, RedRock. Disclosed pre-purchase.
Provider
Physician-led under Medical Director Adam Kennah, M.D.. Available across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review.
Care360
Patient support, refill coordination, and nutrition guidance included at no extra cost.
Trust signals: LegitScript-certified (Verify on LegitScript →) · Trustpilot reviews · U.S. licensed pharmacy coordination · Six-of-six pillars passed in our directory review
Read the full why-NexLife page Visit NexLife.us →